In January 1994, James Tuerff, the president of American General, met with Richard Vie, Unitrin’s chief executive officer, to discuss American General potentially acquiring other companies including Unitrin. Vie replied that Unitrin had excellent prospects as an independent company and had never considered a merger, indicating that Unitrin was not for sale. The Unitrin Board confirmed this position at its February 1994 meeting.
On July 12, 1994, American General sent a letter to Vie proposing a consensual merger transaction in which it would purchase all of Unitrin’s 51.8 million outstanding shares of common stock for $50.50 per share, in cash. The Offer price represented a 30% premium over the market price of Unitrin’s shares. The offer was conditioned on development of a merger agreement and regulatory approval. American General stated it would consider offering a higher price or tax-free alternatives if Unitrin could demonstrate additional value. Upon receiving the offer, the Unitrin Board’s Executive Committee engaged legal counsel and scheduled a telephonic Board meeting for July 18.
The Unitrin Board met for seven hours on July 25, 1994, in Los Angeles with all directors present. Vie reviewed Unitrin’s financial condition and ongoing business strategies while Morgan Stanley presented its opinion that the offer was financially inadequate and legal counsel raised antitrust concerns about the combination. The Board unanimously concluded that the merger proposal was not in the best interests of Unitrin’s shareholders and voted to reject the offer.
Vie sent a letter to American General stating that Unitrin was not for sale and had the financial capacity to pursue all avenues the Board considered appropriate. On August 2, 1994, American General issued a press release announcing its offer, after which trading volume and the market price of Unitrin stock increased. At its regularly scheduled meeting on August 3, the Unitrin Board viewed the public announcement as a hostile act designed to coerce a sale at an inadequate price. The Board unanimously approved a shareholder rights plan and an advance notice bylaw provision. Between August 2 and August 12, Unitrin issued a series of press releases asserting that its stock was undervalued and that the Board had adopted a poison pill.
On August 11, 1994, the Unitrin Board met to consider the Repurchase Program after receiving materials from Morgan Stanley that recommended an open market stock repurchase. The Board voted to authorize the repurchase of up to ten million shares of its outstanding stock. Unitrin publicly announced the Repurchase Program on August 12, noting that the directors who owned 23 percent of the stock would not participate. The company’s certificate of incorporation included a supermajority voting provision. By noon on August 24, Morgan Stanley had purchased nearly five million shares on Unitrin’s behalf at an average price slightly above the offer price.
American General and Unitrin shareholder plaintiffs filed suit in the Court of Chancery seeking to enjoin the Repurchase Program. On August 26, 1994, the Court of Chancery temporarily restrained Unitrin from making any further repurchases. After expedited discovery, briefing, and argument, the Court of Chancery entered a preliminary injunction on October 13, 1994, enjoining further repurchases on the ground that the Repurchase Program was a disproportionate response. The Court of Chancery certified an interlocutory appeal on October 24, 1994, which this Court accepted on October 27, 1994.
View case